Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 143-154
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.143
Table 6 Comparison of adverse event between the two groups, n (%)
| Group | Number of cases | III-IV grade leukopenia | III-IV grade nausea and vomiting | III-IV grade diarrhea | III-IV grade mouth ulcer | III-IV grade abnormal liver and kidney function | III-IV grade thrombocytopenia |
| Observation group | 40 | 8 (20.00) | 11 (27.50) | 13 (32.50) | 9 (22.50) | 15 (38.50) | 10 (25.00) |
| Control group | 40 | 5 (12.50) | 7 (17.50) | 4 (10.00) | 8 (20.00) | 12 (30.00) | 3 (7.50) |
| t/χ2 value | 0.827 | 1.147 | 6.050 | 0.075 | 0.503 | 4.501 | |
| P value | 0.363 | 0.284 | 0.014 | 0.785 | 0.478 | 0.034 |
- Citation: Wang JP, Du JL, Li YY. Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer. World J Gastrointest Oncol 2023; 15(1): 143-154
- URL: https://www.wjgnet.com/1948-5204/full/v15/i1/143.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i1.143